Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

NCT02607813 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
Ovarian Cancer
Melanoma
Other Solid Tumors

Interventions

DRUG: LXH254
DRUG: PDR001

Sponsor

Novartis Pharmaceuticals